ABBV News

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.

AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers.

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.

The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund:

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio.

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.

A look at the moves made by Viking Fund management in the third quarter, including the exits and new stakes and fund's largest positions at the end of Q3.

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.